List of Excipients in Branded Drug CORLANOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amgen Inc	CORLANOR	ivabradine	55513-800	FERRIC OXIDE RED
Amgen Inc	CORLANOR	ivabradine	55513-800	FERRIC OXIDE YELLOW
Amgen Inc	CORLANOR	ivabradine	55513-800	GLYCERIN
Amgen Inc	CORLANOR	ivabradine	55513-800	HYPROMELLOSE
Amgen Inc	CORLANOR	ivabradine	55513-800	LACTOSE MONOHYDRATE
Amgen Inc	CORLANOR	ivabradine	55513-800	MAGNESIUM STEARATE

Corlanor Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Corlanor, the U.S. brand for ivabradine hydrochloride, has a relatively simple solid-dose formulation and a pediatric oral solution. Its main excipient opportunities are not molecule-specific patent substitutes. They are improved pediatric delivery, lactose-free tablets, taste masking, dose flexibility, stability, and manufacturing-cost reduction. The largest commercial opening is a differentiated generic or authorized-generic platform that improves administration without creating unnecessary regulatory risk.

What is Corlanor and which dosage forms are approved?

Corlanor is approved by the FDA for selected patients with stable heart failure with reduced ejection fraction and for certain pediatric patients with stable symptomatic heart failure due to dilated cardiomyopathy. Ivabradine selectively inhibits the cardiac pacemaker current and lowers heart rate without directly reducing myocardial contractility.

The U.S. product portfolio includes:

Dosage form	Strength	Principal use	Excipient strategy
Film-coated tablet	5 mg	Adult and pediatric patients able to swallow tablets	Conventional immediate-release solid dose
Film-coated tablet	7.5 mg	Primarily adult dosing	Conventional immediate-release solid dose
Oral solution	1 mg/mL, equivalent to 5 mg/5 mL	Pediatric patients requiring liquid administration	Liquid stability, palatability, dosing accuracy

The FDA-approved tablet formulation contains lactose monohydrate, magnesium stearate, maize starch, maltodextrin and colloidal anhydrous silica in the tablet core. The film coating contains conventional coating materials, including hypromellose, glycerol, macrogol, titanium dioxide and iron oxide colorant. The oral solution uses a water-based vehicle with sweetening, buffering and preservation components. The exact commercial composition should be taken from the current FDA prescribing information and approved product labeling before development or licensing decisions.[1]

What excipients are used in Corlanor tablets?

Corlanor tablets use a conventional immediate-release formulation:

Functional role	Corlanor tablet excipient
Diluent and bulking agent	Lactose monohydrate
Binder or processing aid	Maltodextrin
Disintegrant	Maize starch
Lubricant	Magnesium stearate
Glidant	Colloidal anhydrous silica
Film former	Hypromellose
Plasticizer and humectant	Glycerol
Coating aid	Macrogol 6000
Opacifier	Titanium dioxide
Colorant	Iron oxide

This composition indicates a low-complexity immediate-release manufacturing process. The core is compatible with wet granulation or other granulation-based approaches, although the commercial manufacturing process is not established solely from the inactive-ingredient list.

The principal formulation vulnerabilities are lactose dependence, dose uniformity at low strength, tablet splitting, coating complexity and pediatric swallowing. None of these issues requires a new active pharmaceutical ingredient. They can be addressed through excipient selection, process optimization or a new dosage form.

What excipients are used in Corlanor oral solution?

The pediatric oral solution is the most commercially differentiated Corlanor presentation. Its formulation priorities are:

1. Accurate measurement at low pediatric doses.
2. Chemical stability of ivabradine hydrochloride in an aqueous environment.
3. Taste acceptability.
4. Microbiological preservation.
5. Compatibility with oral syringes and dosing devices.
6. Supply-chain stability for the liquid vehicle and sweetener system.

The marketed solution uses a water-based composition with glycerin, a sweetening system, citrate buffering, methylparaben and purified water. Hydrochloric acid may be used for pH adjustment. The label identifies the formulation as 1 mg/mL, which simplifies titration relative to a more concentrated liquid but increases bottle volume and shipping weight.[1]

A competing product could pursue a different palatability and preservation system, but any change would require comparative stability, extractables and leachables, preservative-effectiveness, microbial-limit and in-use stability work. The opportunity is strongest where the formulation improves acceptability without changing the dose concentration or requiring a new clinical efficacy study.

What excipient strategy is most attractive for Corlanor generics?

The strongest strategy is a dual-track platform:

Lactose-free immediate-release tablet

The marketed tablet contains lactose monohydrate. A lactose-free formulation could use mannitol, microcrystalline cellulose, dibasic calcium phosphate, silicified microcrystalline cellulose or a co-processed excipient system.

Potential benefits include:

• Broader use by patients with lactose intolerance.
• Reduced dependence on dairy-derived excipient supply.
• A differentiated product profile for hospitals and specialty pharmacies.
• Easier positioning in markets where lactose-free labeling has commercial value.

The technical risk is blend uniformity. Ivabradine hydrochloride is administered at low tablet strengths, so segregation and content-uniformity control are more important than simple tablet hardness. A co-processed filler-binder or dry-granulation approach may reduce process variability.

Pediatric taste-masked tablet or mini-tablet

Some pediatric patients cannot swallow a conventional 5 mg tablet. A scored, dispersible or mini-tablet dosage form could compete with the oral solution while reducing liquid-handling costs.

Possible approaches include:

• Ion-exchange resin complexation.
• Polymer coating of drug particles.
• Multiparticulate pellets.
• Orodispersible tablets.
• Sprinkle capsules containing taste-masked granules.
• Low-volume suspension concentrates.

A taste-masked product would have a more defensible formulation profile than a simple excipient substitution. The commercial challenge is demonstrating rapid release after masking and preventing dose loss when the product is mixed with soft food or liquid.

Improved oral solution

The liquid product offers several design opportunities:

• Sugar-free formulation.
• Alcohol-free formulation.
• Alternative preservative system.
• Improved flavor system.
• Child-resistant bottle and oral-syringe integration.
• Smaller package size for pediatric use.
• Longer in-use stability after opening.
• Reduced precipitation or adsorption to dosing devices.

The most commercially credible improvement is a better-tasting, sugar-free, preservative-robust product with the same 1 mg/mL concentration. A change in concentration could improve shipping economics but would increase medication-error risk and may weaken substitutability.

What formulation patents could protect a Corlanor excipient platform?

A generic tablet with the same active ingredient and conventional excipients is unlikely to obtain meaningful patent protection solely from replacing lactose with mannitol or microcrystalline cellulose. Patent value increases when the formulation solves a measurable technical problem.

Potential claim categories include:

Platform	Potential claim focus	Commercial strength
Taste-masked oral solution	Ivabradine particle coating, resin complex or polymer matrix	Moderate to strong if release and taste data are difficult to design around
Pediatric mini-tablet	Particle-size distribution, dose uniformity and dispersibility	Moderate
Stable oral solution	pH range, preservative system, impurity control and in-use stability	Moderate
Orodispersible tablet	Fast disintegration, palatability and dissolution	Moderate
Lactose-free tablet	Usually weak unless linked to a novel process or performance result	Weak to moderate
Device-integrated solution	Bottle, syringe and dosing interface	Moderate, but often more vulnerable to design-around
Modified release	Release profile and dosing interval	Potentially strong, but requires clinical and regulatory development

A patent application should claim the active ingredient together with measurable formulation parameters, not merely a list of excipients. Useful parameters include dissolution at defined time points, impurity limits, particle-size distribution, pH, viscosity, preservative concentration, in-use stability and taste-response data.

What patents protect Corlanor and when does it lose exclusivity?

Corlanor’s core compound protection is old. Ivabradine was discovered and developed in Europe before U.S. approval in 2015. U.S. commercial risk has therefore shifted from basic composition-of-matter protection toward method-of-use, formulation and regulatory exclusivity.

Relevant public U.S. patent families associated with ivabradine include:

Patent	General subject matter	Strategic relevance
U.S. Patent No. 5,296,482	Ivabradine-related benzazepine compounds	Historical compound protection; original term has expired
U.S. Patent No. 8,557,993	Ivabradine use in heart failure	Method-of-use risk for carved-out or full-label generic products
U.S. Patent No. 9,452,184	Additional ivabradine therapeutic-use claims	Potential Orange Book and Paragraph IV relevance
Later use and formulation families	Heart-failure dosing, patient selection or formulation features	Must be checked against the live FDA Orange Book record

The precise Orange Book expiration and pediatric-extension status must be determined from the current listing for NDA 206143. Patent term adjustment, patent-term extension, terminal disclaimers and pediatric exclusivity can alter the effective date. A filing strategy should not rely on the expiration date of the original ivabradine compound patent.

FDA approved Corlanor in April 2015. The product received three-year new clinical investigation exclusivity for the approved heart-failure indication, and pediatric exclusivity may have extended applicable listed protection by six months. Those regulatory periods have expired.[1,2]

What is the Orange Book status of Corlanor?

Corlanor is listed in the FDA Orange Book under NDA 206143. The commercial significance of the listing is that an ANDA applicant must address each currently listed patent through a Paragraph I, II, III or IV certification, or through a section viii statement for a method-of-use patent where applicable.[2]

For an excipient-focused generic, the principal patent risks are:

• A formulation patent covering the tablet or oral solution.
• A method-of-use patent covering heart-failure treatment.
• A dosing or patient-selection patent.
• A patent covering a pediatric liquid or administration method.
• A patent that remains listed even though the commercial formulation has changed.

A Paragraph IV certification can create Hatch-Waxman litigation and a potential 30-month stay of approval if the NDA holder files suit within the statutory period. A section viii carve-out can avoid infringement of a method-of-use claim, but the generic label must omit the protected use. That approach is commercially difficult when the protected indication is the central use of Corlanor.[3]

Which companies are challenging Corlanor?

The principal competitive threat is from ANDA applicants seeking approval for ivabradine tablets and, potentially, an oral solution. Public FDA records and litigation databases should be reviewed for applicant-specific Paragraph IV notices, district-court complaints and settlement terms before a transaction closes.

For commercial planning, an applicant should assume three generic-launch scenarios:

Scenario	Timing profile	Commercial effect
First filer with no litigation delay	Launch at or shortly after relevant patent expiry	Highest price erosion and strongest first-mover position
Paragraph IV litigation	Approval can be delayed by litigation or settlement	Preserves brand share longer but raises legal cost
Section viii carve-out	Approval limited to non-protected indications	May produce a narrow market and pharmacy-substitution barriers

Unlike a biologic, Corlanor has no biosimilar pathway. It is a small-molecule product and competes through the ANDA pathway. The relevant regulatory barriers are bioequivalence, formulation sameness where required, label restrictions and patent certification, not immunogenicity or biosimilar interchangeability.[3]

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue Corlanor-related business in four segments.

Pediatric oral-liquid excipients

High-value products include:

• Low-sugar or sugar-free sweeteners.
• Flavor systems that mask ivabradine bitterness.
• Preservative systems compatible with acidic aqueous formulations.
• Buffer systems that control degradation.
• Suspending or viscosity-modifying agents for alternative liquid products.
• Low-extractables packaging components.

A supplier with taste-masking data in pediatric cardiovascular medicines can differentiate more effectively than a commodity excipient supplier.

Direct-compression systems

A co-processed excipient that supports low-dose content uniformity, rapid disintegration and robust tablet compression could replace the existing starch-maltodextrin-lactose system. The strongest sales proposition is manufacturing performance, not a simple inactive-ingredient substitution.

Lactose-free and allergen-positioned platforms

Lactose-free products may appeal to selected patients and institutional buyers. The opportunity is commercially real but limited by the relatively low clinical burden of lactose in most patients. The product must justify a price or procurement preference through tolerability, supply continuity or manufacturing efficiency.

Packaging and dosing systems

The oral solution creates opportunities for:

• Oral syringes calibrated for low doses.
• Bottle adapters.
• Child-resistant closures.
• Unit-dose liquid packaging.
• Low-sorption polymer containers.
• Integrated dosing systems that reduce medication errors.

Device claims can supplement formulation claims, although device patents are often easier to design around than composition claims.

How strong is the Corlanor formulation patent estate?

The likely strength of the formulation estate is moderate rather than high. The marketed tablet uses common excipients and does not depend on a complex delivery technology. A competitor can probably design around the commercial formulation with a different filler, binder or coating system while maintaining immediate release.

The oral solution has greater technical defensibility because taste, pH, preservative compatibility, impurity formation and in-use stability interact. A patent covering a specific formulation-performance combination could delay direct substitution, particularly if it is linked to pediatric dosing.

The strongest defensible platform would combine:

• A defined ivabradine particle or salt form.
• A reproducible taste-masking mechanism.
• A specified dissolution profile.
• Low degradation-product formation.
• Stable storage and in-use performance.
• A pediatric administration device.

How does Corlanor compare with competing heart-failure products?

Corlanor competes with pharmacologic heart-failure therapies that have broader indications and larger treatment populations, including beta blockers, angiotensin-receptor-neprilysin inhibitors, SGLT2 inhibitors and mineralocorticoid receptor antagonists. Its differentiator is heart-rate reduction through sinoatrial-node modulation in selected patients, not broad neurohormonal blockade.

That positioning affects excipient economics. The adult tablet market may experience substantial price pressure after generic entry. The pediatric liquid market is narrower and may sustain better margins if the product offers reliable dosing, palatability and supply continuity.

Corlanor does not have a biosimilar risk profile. Its commercial exposure is tied to generic substitution and method-of-use patent enforcement.

What revenue exposure does Corlanor create?

Amgen does not generally report Corlanor revenue as a separately disclosed major product line in its consolidated public reporting. A transaction model should therefore estimate exposure from prescription volume, net price, indication mix, payer coverage and the percentage of pediatric liquid use rather than rely on a separately reported brand-revenue line.[4]

The most exposed segment is the adult tablet business because it is easier for multiple ANDA suppliers to reproduce. The pediatric oral solution is more defensible commercially because it requires liquid manufacturing, taste acceptance, packaging validation and pediatric-use support.

Key Takeaways

• Corlanor uses conventional immediate-release tablets and a pediatric oral solution.
• The main excipient opportunity is a lactose-free tablet, improved pediatric liquid or taste-masked pediatric solid.
• A simple excipient substitution is unlikely to produce strong patent protection.
• Taste masking, liquid stability, pediatric dosing and device integration offer better patent and commercial positions.
• Corlanor is an ANDA product, not a biosimilar product.
• The core ivabradine compound patent is historical; live risk centers on method-of-use, formulation and dosing patents.
• Orange Book patents and Paragraph IV notices should determine launch timing and litigation exposure.
• Adult tablets face greater price erosion risk than pediatric oral solution products.
• Excipient suppliers should compete on performance data, supply reliability and regulatory support rather than commodity pricing alone.

FAQs

Can a generic Corlanor tablet use different excipients?

Yes. An ANDA applicant can generally use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. The applicant must evaluate safety, manufacturing performance and dissolution.

Is a lactose-free Corlanor formulation commercially attractive?

It can be attractive as a differentiated product, but lactose-free status alone is unlikely to support durable pricing power. The strongest case combines lactose elimination with improved content uniformity, tablet robustness or pediatric usability.

Could an oral suspension replace Corlanor oral solution?

Potentially, but the product would require development of dose uniformity, physical stability, microbial control, redispersibility, preservative effectiveness, in-use stability and device compatibility. It may also face a more complex regulatory and substitution analysis than an equivalent solution.

Can a taste-masked ivabradine product receive patent protection?

Yes, if the claims cover a non-obvious masking mechanism and measurable performance, such as bitterness reduction, dissolution, stability or pediatric administration. A claim limited to a routine flavor or sweetener substitution would be weaker.

What is the most defensible Corlanor licensing opportunity?

A pediatric delivery platform combining taste masking, stable liquid or mini-tablet dosage, accurate dosing and a validated administration device is more defensible than a conventional tablet excipient replacement.

References

1. U.S. Food and Drug Administration. (2024). Corlanor (ivabradine) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an ANDA.
4. Amgen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
5. United States Patent and Trademark Office. (1994). U.S. Patent No. 5,296,482: Benzazepine derivatives.
6. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,557,993: Methods of treating heart failure using ivabradine.
7. United States Patent and Trademark Office. (2016). U.S. Patent No. 9,452,184: Therapeutic use of ivabradine.